U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H32N2O4.2H2O
Molecular Weight 460.5631
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALVIMOPAN

SMILES

O.O.C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C3=CC=CC(O)=C3

InChI

InChIKey=USPVLEIQIUNQGE-DBFLIVQGSA-N
InChI=1S/C25H32N2O4.2H2O/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19;;/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30);2*1H2/t18-,20-,25+;;/m0../s1

HIDE SMILES / InChI

Molecular Formula C25H32N2O4
Molecular Weight 424.5326
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8057274 | http://adisinsight.springer.com/drugs/800003539

Alvimopan (LY246736, ADL 8-2698, trade name Entereg) is a potent, peripherally selective mu-opioid receptor antagonist. Alvimopan was developed by Adolor Corporation (now Cubist Pharmaceuticals) and GlaxoSmithKline for the treatment of postoperative ileus. Postoperative ileus is the impairment of gastrointestinal motility after intra-abdominal surgery or other non-abdominal surgeries. This may potentially delay gastrointestinal recovery and hospital discharge until its resolution. Morphine and other mu-opioid receptor agonists are universally used for the treatment of acute postsurgical pain; however, they are known to have an inhibitory effect on gastrointestinal motility and may prolong the duration of postoperative ileus. Following oral administration, alvimopan antagonizes the peripheral effects of opioids on gastrointestinal motility and secretion by competitively binding to gastrointestinal tract mu-opioid receptors.

Originator

Curator's Comment: # Eli Lilly

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.77 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
ENTEREG

Approved Use

ENTEREG is a peripherally acting μ-opioid receptor antagonist indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis.

Launch Date

2008
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
10.98 ng/mL
12 mg 2 times / day multiple, oral
dose: 12 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALVIMOPAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
40.2 ng × h/mL
12 mg 2 times / day multiple, oral
dose: 12 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALVIMOPAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.5 h
12 mg 2 times / day multiple, oral
dose: 12 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALVIMOPAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
20%
12 mg 2 times / day multiple, oral
dose: 12 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALVIMOPAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
120 mg single, oral
Highest studied dose
Dose: 120 mg
Route: oral
Route: single
Dose: 120 mg
Sources:
healthy, adult
48 mg 1 times / day multiple, oral
Highest studied dose
Dose: 48 mg, 1 times / day
Route: oral
Route: multiple
Dose: 48 mg, 1 times / day
Sources:
healthy, adult
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Other AEs: Ascites, Ileus...
Other AEs:
Ascites (serious, 1 patient)
Ileus (serious, 1 patient)
Electrolyte imbalance (serious, 1 patient)
Failure to thrive (serious, 1 patient)
Syncope (serious, 1 patient)
Wound infection (serious, 2 patients)
Wound complication (serious, 1 patient)
Mania (serious, 1 patient)
Hypertension (below serious, 3 patients)
Constipation (below serious, 18 patients)
Diarrhea (below serious, 6 patients)
Dyspepsia (below serious, 1 patient)
Nausea (below serious, 20 patients)
Vomiting (below serious, 9 patients)
Anorexia (below serious, 4 patients)
Esophagitis (below serious, 1 patient)
Gastroparesis (below serious, 1 patient)
Weight loss (below serious, 3 patients)
Leukocytosis (below serious, 4 patients)
International normalized ratio increased (below serious, 1 patient)
Electrolyte imbalance (below serious, 8 patients)
Hypomagnesemia (below serious, 2 patients)
Elevated liver enzymes (below serious, 2 patients)
Delirium (below serious, 3 patients)
Insomnia (below serious, 1 patient)
Sensory neuropathy (below serious, 3 patients)
Cystostomy (below serious, 1 patient)
Pelvic abscess (below serious, 1 patient)
Urinary tract obstruction (below serious, 1 patient)
Allergic reaction to chemotherapy (below serious, 1 patient)
Pneumonitis (below serious, 2 patients)
Pneumothorax (below serious, 2 patients)
Wound infection (below serious, 7 patients)
Skin infection (below serious, 2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Allergic reaction to chemotherapy below serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Cystostomy below serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Dyspepsia below serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Esophagitis below serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Gastroparesis below serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Insomnia below serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
International normalized ratio increased below serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Pelvic abscess below serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Urinary tract obstruction below serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Constipation below serious, 18 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Elevated liver enzymes below serious, 2 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Hypomagnesemia below serious, 2 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Pneumonitis below serious, 2 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Pneumothorax below serious, 2 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Skin infection below serious, 2 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Nausea below serious, 20 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Delirium below serious, 3 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Hypertension below serious, 3 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Sensory neuropathy below serious, 3 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Weight loss below serious, 3 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Anorexia below serious, 4 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Leukocytosis below serious, 4 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Diarrhea below serious, 6 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Wound infection below serious, 7 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Electrolyte imbalance below serious, 8 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Vomiting below serious, 9 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Ascites serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Electrolyte imbalance serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Failure to thrive serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Ileus serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Mania serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Syncope serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Wound complication serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
Wound infection serious, 2 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no
no
no
no
no
no
no (co-administration study)
Comment: based on study using MDCKII cells, digoxin transport not affected
Page: 66, 67
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist.
2001 Nov
Alvimopan (Adolor/GlaxoSmithKline).
2002 Oct
Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.
2003
Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus.
2004 Oct
Preclinical studies of opioids and opioid antagonists on gastrointestinal function.
2004 Oct
Peripheral opiate action on afferent fibres supplying the rat intestine.
2004 Oct
Basic and clinical pharmacology of new motility promoting agents.
2005 Oct
Alvimopan for the management of postoperative ileus.
2005 Sep
Peripheral opioids for functional GI disease: a reappraisal.
2006
Optimizing perioperative management of patients undergoing colorectal surgery: what is new?
2006 Apr
A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy.
2006 Aug
Pain management research goes beyond the obvious.
2006 Dec 1
Current gut-directed therapies for irritable bowel syndrome.
2006 Jul
Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus.
2007
Treatment of opioid-induced gut dysfunction.
2007 Feb
Meta-analysis: Alvimopan vs. placebo in the treatment of post-operative ileus.
2007 Jan 1
Patterns of gastrointestinal recovery after bowel resection and total abdominal hysterectomy: pooled results from the placebo arms of alvimopan phase III North American clinical trials.
2007 Jul
Cancer-related constipation.
2007 Jul
Novel and alternative therapies for childhood constipation.
2007 Jun
Pharmacologic management of postoperative ileus: the next chapter in GI surgery.
2007 Mar
Alvimopan accelerates gastrointestinal recovery after bowel resection regardless of age, gender, race, or concomitant medication use.
2007 Oct
Is alvimopan a safe and effective treatment for postoperative ileus?
2007 Sep
Opioid-induced constipation in intensive care patients: relief in sight?
2008
Mu-opioid antagonists for opioid-induced bowel dysfunction.
2008 Apr 16
Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study.
2008 Aug 1
Alvimopan (Entereg) for postoperative ileus.
2008 Dec 1
Opioid-induced bowel dysfunction.
2008 Jan
Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trials.
2008 May
Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway.
2008 Nov
Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials.
2008 Sep
New drugs: methylnaltrexone bromide, alvimopan, and rilonacept.
2008 Sep-Oct
Economic analysis of alvimopan in North American Phase III efficacy trials.
2009 Aug 1
Pathogenesis and management of postoperative ileus.
2009 Feb
Opioid receptors in the gastrointestinal tract.
2009 Jun 5
Comment on alvimopan guidelines.
2009 Sep
Alvimopan (entereg) for the management of postoperative ileus in patients undergoing bowel resection.
2010 Jan
The effects of a short course of antibiotics on alvimopan and metabolite pharmacokinetics.
2010 Mar
Patents

Sample Use Guides

12 mg administered 30 minutes to 5 hours prior to surgery followed by 12 mg twice daily for up to 7 days for a maximum of 15 doses
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: In morphine-naive guinea pig ileum alvimopan increased, the amplitude of electrically evoked contractions and spontaneous mechanical activity.
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:02:41 GMT 2023
Edited
by admin
on Fri Dec 15 16:02:41 GMT 2023
Record UNII
677C126AET
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALVIMOPAN
DASH   HSDB   ORANGE BOOK   USAN   VANDF  
USAN  
Official Name English
ENTEREG
Brand Name English
ALVIMOPAN DIHYDRATE [MI]
Common Name English
ALVIMOPAN [VANDF]
Common Name English
LY-246736
Code English
ALVIMOPAN [ORANGE BOOK]
Common Name English
ADL-8-2698
Code English
ALVIMOPAN [HSDB]
Common Name English
[[(2S)-2-[[(3R,4R)-4-(3-Hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl]-3-phenylpropanoyl]amino]acetic acid dihydrate
Systematic Name English
LY-246736 DIHYDRATE
Code English
ALVIMOPAN [USAN]
Common Name English
ADL 8-2698
Code English
LY246736
Code English
ALVIMOPAN DIHYDRATE [MART.]
Common Name English
GLYCINE, N-(2-((4-(3-HYDROXYPHENYL)-3,4-DIMETHYL-1-PIPERIDINYL)METHYL)-1-OXO-3-PHENYLPROPYL)-, DIHYDRATE, (3R-(1(S*),3.ALPHA.,4.ALPHA.))-
Common Name English
ALVIMOPAN DIHYDRATE
MART.   MI  
Common Name English
Classification Tree Code System Code
WHO-VATC QA06AH02
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
NCI_THESAURUS C681
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
WHO-ATC A06AH02
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
NDF-RT N0000175691
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
Code System Code Type Description
MERCK INDEX
m1636
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C49096
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
PRIMARY
USAN
MM-72
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
PRIMARY
DRUG CENTRAL
143
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
PRIMARY
DRUG BANK
DB06274
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
PRIMARY
FDA UNII
677C126AET
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
PRIMARY
MESH
C419502
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
PRIMARY
ChEMBL
CHEMBL270190
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
PRIMARY
SMS_ID
300000032193
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
PRIMARY
PUBCHEM
5488547
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
PRIMARY
WIKIPEDIA
ALVIMOPAN
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
PRIMARY
EPA CompTox
DTXSID40168794
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
PRIMARY
DAILYMED
677C126AET
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
PRIMARY
IUPHAR
7471
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
PRIMARY
CAS
170098-38-1
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
PRIMARY
RXCUI
480639
Created by admin on Fri Dec 15 16:02:41 GMT 2023 , Edited by admin on Fri Dec 15 16:02:41 GMT 2023
PRIMARY RxNorm
Related Record Type Details
BINDER->LIGAND
BINDING
ANHYDROUS->SOLVATE
TARGET -> AGONIST
BINDING
Ki
TARGET -> AGONIST
BINDING
Ki
TARGET -> AGONIST
BINDING
Ki
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC